<DOC>
	<DOCNO>NCT00002451</DOCNO>
	<brief_summary>The purpose study see safe give indinavir ( IDV ) ritonavir ( RTV ) combination stavudine ( d4T ) lamivudine ( 3TC ) HIV-positive patient never receive anti-HIV therapy . This study look effectiveness drug combination side effect .</brief_summary>
	<brief_title>Safety Effectiveness Giving Indinavir , Ritonavir , Stavudine , Lamivudine HIV-Infected Patients Who Have Never Received Anti-HIV Drugs</brief_title>
	<detailed_description>Patients enter study initiate antiretroviral therapy . For 24 week patient receive daily dosage IDV , RTV , 3TC , d4T . Patients see Day 1 Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 physical examination , pregnancy testing , blood sample monitor CD4 count viral load . On Day 14 , blood drawn frequently 24 hour IDV RTV pharmacokinetic sampling . The incidence serious drug-related adverse event adverse event lead study discontinuation tabulate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Are least 18 year old . Have viral load 5,000 copies/ml great . Have CD4 count least 50 cells/mm3 . Exclusion Criteria Patients eligible study : Have take antiretroviral ( antiHIV ) agent . Are pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>